Testing effectiveness (Phase 2)Study completedNCT04256707
What this trial is testing
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
Who this might be right for
Non-Small Cell Lung Carcinoma (NSCLC)Colorectal Cancer (CRC)Other Solid Tumors
Karyopharm Therapeutics Inc 126